Cytek Biosciences, Inc. · NASDAQ:CTKB
Cytek Biosciences — Q1 2026 Earnings Presentation
14 slides from Cytek Biosciences's earnings presentation, May 7, 2026
Slide 1: Q1 2026 Earnings Presentation
Q1 2026 Earnings Presentation May 7, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s future financial performance, including its outlook
Slide 3: Q1 2026 Revenue Results
Q1 2026 Revenue Results1 Service Revenue $62.1M Product Revenue +8% Y/Y $52.3 +2% Y/Y $15.5 Q1 2026 Commentary $45.6 $44.1 $41.5 -2% Y/Y +6% Y/Y -8% Y/Y $14.2 Resilient performance despite persistent challenges in the life science tools industry, $14.2 demonstrating technology strength and $15.4 $13
Slide 4: Revenue by Geographic Region
Revenue by Geographic Region1 Other APAC EMEA Q1 2026 Commentary United States 1 $62.1M US: Revenue was up 32% Y/Y driven by broad- +8% Y/Y based growth across leading academic $52.3 3.7 institutions and biopharma companies +2% Y/Y $45.6 $44.1 1.6 13.2 $41.5 -2% Y/Y +6% Y/Y EMEA: Revenue was down 7%
Slide 5: Recurring Revenue Businesses Continue to Grow Steadily
Recurring Revenue Businesses Continue to Grow Steadily1 Q1 ’25 TTM Q1 ’26 TTM $204.2M $197.1M 19% Y/Y Growth 31% $71.8M 35% of Total Revenue $60.2M of Total Revenue $136.9M $132.5M Q1 2025 Q1 2026 Other Revenue Recurring Revenue 1. Recurring revenue is comprised of service and reagent revenue; Other
Slide 6: Our Strategic Business Pillars
Our Strategic Business Pillars1 Instruments Applications Bioinformatics Clinical1 Expanded to a total installed base of 3,789 Cytek instruments, adding 125 units in the first quarter Total instrument unit volume increased 9% Y/Y, including a 3% Y/Y increase of FSP instruments Market reception for Cy
Slide 7: Creating New Business Units to Drive Growth
Creating New Business Units to Drive Growth Aligns sales, marketing and R&D resources on distinct customer needs to accelerate Cytek’s growth 1 2 3 Research Technology Solutions and Clinical Service Business Unit Business Unit Business Unit High-end instruments to Low/mid-range instruments and Syste
Slide 8: Revenue Mix
Revenue Mix Product & Service1 By Region $44.1M $44.1M $41.5M $41.5M $1.2 $2.5 $7.8 $15.4 $13.3 $8.9 $10.8 $11.6 $28.1 $28.8 $24.4 Other Service $18.5 APAC Revenue EMEA Product Revenue United States Q1 2025 Q1 2026 Q1 2025 Q1 2026 1. Recurring revenue is comprised of service and reagent revenue; Oth
Slide 9: Q1 2026 Financial Overview
Q1 2026 Financial Overview $ in millions Q1 2025 Q1 2026 YoY Total Revenue $41.5 $44.1 6% Gross Profit $20.2 $21.3 5% Adjusted Gross Margin1 52% 51% NM Operating Expenses: Research and Development $9.7 $9.6 (1)% Sales and Marketing $12.5 $11.6 (7)% General and Administrative2 $12.9 $18.5 43% Total O
Slide 10: Reaffirming 2026 Revenue Guidance
FY 2026 Revenue1 Reaffirming 2026 $205 - $212 Revenue Guidance million +2 to +5% Y/Y growth 1. Assumes no change from current currency exchange rates 10
Slide 11: 2026 Strategic Priorities
2026 Strategic Priorities Attractive Financial Profile Growing Recurring Revenue Well-positioned to Technology Platform deliver long-term Leader Drive reagent and profitable, Global Diversification service businesses sustainable growth Advance technological benefitting from through differentiated le
Slide 12: Appendix
“CYTE K* TRANSCEND THE CONVENTIONAL. Appendix
Slide 13: Reconciliation of GAAP to Non-GAAP Measures (Unaudited)
Reconciliation of GAAP to Non-GAAP Measures (Unaudited) Three months ended (In thousands) March 31, 2026 March 31, 2025 (Unaudited) (Unaudited) GAAP gross profit $ 21,254 $ 20,157 Stock based compensation 729 1,086 Amortization of acquisition-related intangible assets 494 493 Non-GAAP adjusted gross
Slide 14: Thank You
e - TRANSCEND THE CONVENTIONAL ‘Thank You